- Research & Development
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report13 Apr 2020
The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.
BERG, a clinical-stage biotech company that uses AI to research diseases and develop innovative treatments, has been awarded a spot in Frost & Sullivan's first-ever Frost Radar AI in Drug Discovery report in the pharmaceutical industry.
Frost & Sullivan's decision to recognize BERG as a biotech pioneer is based on its strong innovation trajectory, sustained growth over the last decade and being one of the first companies to develop corporate partnerships in this application.
BERG's capabilities also uniquely position the company to apply AI technologies to patient data to better understand the biological drivers of disease.
Amol Jadhav, Industry Analyst, Transformational Health, said: "Their inventive research efforts, understanding of diagnostics and drug development combined with the AI-powered approach have put them at the forefront of precision medicine."
Frost & Sullivan identified BERG as a Visionary in AI drug discovery for a number of reasons:
Dr Niven R. Narain, BERG's President and Chief Executive Officer said they will continue to work with partners to identify "what's next" across multiple sectors including oncology, neurology and rare diseases.
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation